HOXC6 and colorectal carcinoma: These findings not only fill the knowledge gap regarding molecular mechanisms of EMT and immune microenvironment crosstalk, but also provide novel biomarkers (e.g., HOXC6) and potential therapeutic targets for precision classification and targeted intervention in CRC.